



Description générale

Ritonavir is recommended for use in combination with other protease inhibitors as a pharmacological booster in the prevention and treatment of HIV/AIDS, and not as an antiretroviral in its own right.

INN	Ritonavir
Codes ATC	J05AE03
Type de médicament	Chemical agent
Historique des statuts LME	Ajouté pour la première fois en 2002 (TRS 914) pour Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Wikipédia	Ritonavir ↗
DrugBank	Ritonavir ↗

Recommandations

Section Antiretrovirals > Protease inhibitors

Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

